Literature DB >> 24912776

Modeling cancer glycolysis under hypoglycemia, and the role played by the differential expression of glycolytic isoforms.

Alvaro Marín-Hernández1, Sayra Y López-Ramírez, Isis Del Mazo-Monsalvo, Juan C Gallardo-Pérez, Sara Rodríguez-Enríquez, Rafael Moreno-Sánchez, Emma Saavedra.   

Abstract

UNLABELLED: The effect of hypoglycemia on the contents of glycolytic proteins, activities of enzymes/transporters and flux of HeLa and MCF-7 tumor cells was experimentally analyzed and modeled in silico. After 24 h hypoglycemia (2.5 mm initial glucose), significant increases in the protein levels of glucose transporters 1 and 3 (GLUT 1 and 3) (3.4 and 2.1-fold, respectively) and hexokinase I (HKI) (2.3-fold) were observed compared to the hyperglycemic standard cell culture condition (25 mm initial glucose). However, these changes did not bring about a significant increase in the total activities (Vmax ) of GLUT and HK; instead, the affinity of these proteins for glucose increased, which may explain the twofold increased glycolytic flux under hypoglycemia. Thus, an increase in more catalytically efficient isoforms for two of the main controlling steps was sufficient to induce increased flux. Further, a previous kinetic model of tumor glycolysis was updated by including the ratios of GLUT and HK isoforms, modified pyruvate kinase kinetics and an oxidative phosphorylation reaction. The updated model was robust in terms of simulating most of the metabolite levels and fluxes of the cells exposed to various glycemic conditions. Model simulations indicated that the main controlling steps were glycogen degradation > HK > hexosephosphate isomerase under hyper- and normoglycemia, and GLUT > HK > glycogen degradation under hypoglycemia. These predictions were experimentally evaluated: the glycolytic flux of hypoglycemic cells was more sensitive to cytochalasin B (a GLUT inhibitor) than that of hyperglycemic cells. The results indicated that cancer glycolysis should be inhibited at multiple controlling sites, regardless of external glucose levels, to effectively block the pathway. DATABASE: The mathematical models described here have been submitted to the JWS Online Cellular Systems Modelling Database and can be accessed at http://jjj.mib.ac.uk/database/achcar/index.html. [Database section added 21 July 2014 after original online publication].
© 2014 FEBS.

Entities:  

Keywords:  GLUT3; HKI; flux control coefficient; glycolytic isoforms; metabolic control analysis

Mesh:

Substances:

Year:  2014        PMID: 24912776     DOI: 10.1111/febs.12864

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  20 in total

1.  Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.

Authors:  Nusrat Chowdhury; Imran Vhora; Ketan Patel; Ravi Doddapaneni; Arindam Mondal; Mandip Singh
Journal:  Pharm Res       Date:  2017-09-05       Impact factor: 4.200

2.  [6]-Gingerol inhibits de novo fatty acid synthesis and carnitine palmitoyltransferase-1 activity which triggers apoptosis in HepG2.

Authors:  Hathaichanok Impheng; Lysiane Richert; Dumrongsak Pekthong; C Norman Scholfield; Sutatip Pongcharoen; Ittipon Pungpetchara; Piyarat Srisawang
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

3.  Consequences of a Metabolic Glucose-Depletion on the Survival and the Metabolism of Cultured Rat Astrocytes.

Authors:  Christian Arend; Eric Ehrke; Ralf Dringen
Journal:  Neurochem Res       Date:  2019-02-20       Impact factor: 3.996

4.  Inhibition of Non-flux-Controlling Enzymes Deters Cancer Glycolysis by Accumulation of Regulatory Metabolites of Controlling Steps.

Authors:  Álvaro Marín-Hernández; José S Rodríguez-Zavala; Isis Del Mazo-Monsalvo; Sara Rodríguez-Enríquez; Rafael Moreno-Sánchez; Emma Saavedra
Journal:  Front Physiol       Date:  2016-09-23       Impact factor: 4.566

5.  Glycoprotein Ib activation by thrombin stimulates the energy metabolism in human platelets.

Authors:  Norma Corona de la Peña; Manuel Gutiérrez-Aguilar; Ileana Hernández-Reséndiz; Álvaro Marín-Hernández; Sara Rodríguez-Enríquez
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

6.  Cancer cell spheroids are a better screen for the photodynamic efficiency of glycosylated photosensitizers.

Authors:  Patrícia M R Pereira; Naxhije Berisha; N V S Dinesh K Bhupathiraju; Rosa Fernandes; João P C Tomé; Charles Michael Drain
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

7.  Computational Model Predicts the Effects of Targeting Cellular Metabolism in Pancreatic Cancer.

Authors:  Mahua Roy; Stacey D Finley
Journal:  Front Physiol       Date:  2017-04-12       Impact factor: 4.566

8.  Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis.

Authors:  Guanhua Song; Qiqi Lu; Hua Fan; Xiumei Zhang; Luna Ge; Ruisong Tian; Shiguan Wang; Tingting Feng; Jihong Pan; Jingjing Feng; Yabo Xiao; Xin Yi; Ningxin Ren; Lin Wang
Journal:  Arthritis Res Ther       Date:  2019-04-03       Impact factor: 5.156

9.  The kinetic characteristics of human and trypanosomatid phosphofructokinases for the reverse reaction.

Authors:  Peter M Fernandes; James Kinkead; Iain W McNae; Frédéric Bringaud; Paul A M Michels; Malcolm D Walkinshaw
Journal:  Biochem J       Date:  2019-01-18       Impact factor: 3.857

10.  An experimental-numerical investigation on the effects of macroporous scaffold geometry on cell culture parameters.

Authors:  Hadis Eghbali; Michele M Nava; Gabriella Leonardi; Davod Mohebbi-Kalhori; Roberto Sebastiano; Abdolreza Samimi; Manuela T Raimondi
Journal:  Int J Artif Organs       Date:  2017-04-13       Impact factor: 1.595

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.